Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth A Bauer

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
JAMA|March 3, 2025
Population-Scale Studies of Protein S Abnormalities and ThrombosisSharjeel A Chaudhry, Amelia K Haj, Justine Ryu, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
Haematologica|March 17, 2009
F9 Malmö, factor IX and deep vein thrombosisIrene D Bezemer, Andre R Arellano, Carmen H Tong, et al.
Thrombosis and Haemostasis|June 6, 2007
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher, Bengt I Eriksson, Kenneth A Bauer, et al.
Lancet (London, England)|May 5, 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie, Michael R Lassen, Bruce L Davidson, et al.
Clinical Pharmacokinetics|March 1, 2008
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck, Bengt I Eriksson, Kenneth A Bauer, et al.
Critical Pathways in Cardiology|July 30, 2013
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient CareBenjamin A Steinberg, Philip D Beckley, Thomas F Deering, et al.
JCI Insight|January 18, 2019
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I Zwicker, Benjamin L Schlechter, Jack D Stopa, et al.
Journal of Thrombosis and Haemostasis : JTH|April 30, 2019
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort studyClive Kearon, Sameer Parpia, Frederick A Spencer, et al.
Blood Advances|February 5, 2025
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulationCho-Han Chiang, Junmin Song, Yu-Cheng Chang, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
JAMA|March 3, 2025
Population-Scale Studies of Protein S Abnormalities and ThrombosisSharjeel A Chaudhry, Amelia K Haj, Justine Ryu, et al.
British Journal of Haematology|December 18, 2012
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)Jeffrey I Zwicker, Howard A Liebman, Kenneth A Bauer, et al.
Haematologica|March 17, 2009
F9 Malmö, factor IX and deep vein thrombosisIrene D Bezemer, Andre R Arellano, Carmen H Tong, et al.
Thrombosis and Haemostasis|June 6, 2007
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studiesWilliam D Fisher, Bengt I Eriksson, Kenneth A Bauer, et al.
Lancet (London, England)|May 5, 2009
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialAlexander G G Turpie, Michael R Lassen, Bruce L Davidson, et al.
Clinical Pharmacokinetics|March 1, 2008
Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgeryWolfgang Mueck, Bengt I Eriksson, Kenneth A Bauer, et al.
Critical Pathways in Cardiology|July 30, 2013
Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient CareBenjamin A Steinberg, Philip D Beckley, Thomas F Deering, et al.
JCI Insight|January 18, 2019
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancerJeffrey I Zwicker, Benjamin L Schlechter, Jack D Stopa, et al.
Journal of Thrombosis and Haemostasis : JTH|April 30, 2019
Long-term risk of recurrence in patients with a first unprovoked venous thromboembolism managed according to d-dimer results; A cohort studyClive Kearon, Sameer Parpia, Frederick A Spencer, et al.
Blood Advances|February 5, 2025
Glucagon-like peptide 1 receptor agonists and venous thromboembolism in type 2 diabetes: a target trial emulationCho-Han Chiang, Junmin Song, Yu-Cheng Chang, et al.
Pageof 10